Indian Immunologicals denies seized ‘substandard’ Abhayrab vials were its product
Indian Immunologicals says 83,370 Abhayrab vials from batch KE25012 seized in Delhi differed in 17 ways from its retained samples. The vaccine maker has asked regulators to trace the source, saying genuine supplies moved only through authorised channels.
What happened
Indian Immunologicals says substandard, misbranded Abhayrab vials seized in Delhi were not its product, citing 17 differences from retained samples. It asked
Key facts
- Batch KE25012
- 83,370 vials
- 17 differences
- 210 million doses
- 40% domestic rabies vaccine market share
- Batch KA24014
Why this matters
Any vaccine distribution partnership or acquisition should prioritize authenticated supply chains, channel controls and rapid counterfeit-response capabilities.
What to watch
- Regulator laboratory findings on whether the seized vials are counterfeit, falsified, improperly stored or genuine product.
- Identification of the distributor, pharmacy, hospital or procurement channel from which the 83,370 vials originated.
- Any recall, stop-sale, public health advisory, FIR, licence suspension or named enforcement action.
- Reports of adverse events, treatment failures or patient exposure connected to the seized inventory.
- Evidence that other batches, cities or rabies-vaccine brands are involved.
- Changes in Abhayrab availability, institutional tenders or emergency purchasing by hospitals and public-health programs.
- Drug regulators are likely to conduct forensic comparison of seized vials, packaging, cold-chain records and batch documentation against manufacturer-retained samples.
- Indian Immunologicals may publish batch-authentication guidance, authorised-distributor lists, packaging identifiers and provider advisories.
- Hospitals, pharmacies and government buyers may quarantine disputed inventory and require invoice-level traceability before administering or replenishing stock.
- Authorities may expand inspections to wholesalers, transporters and pharmacies in Delhi and other markets where the batch number or similar packaging appears.
- Competitors and authorised distributors may benefit from temporary procurement shifts if buyers prioritise verifiable supply.